

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				<i>Complete if Known</i>
Sheet	1	of	14	Application Number 10/587,052
				Filing Date April 9, 2007
				First Named Inventor Paul A. Bunn Jr.
				Art Unit 1642
				Examiner Name Sean E. Aeder
				Attorney Docket Number 5941-65-PUS

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5369108	11/29/94	Breslow et al.	
	2	5445934	08/29/95	Fodor et al.	
	3	5700811	12/23/97	Breslow et al.	
	4	5932616	08/03/99	Breslow et al.	
	5	6040138	03/21/00	Lockhart et al.	
	6	6087367	07/11/00	Breslow et al.	
	7	6177248	01/23/01	Oliner et al.	
	8	6511990	01/28/03	Breslow et al.	
	9	2002/0045591	04/18/02	Geiger et al.	
	10	2003/0114504	06/19/03	Webster et al.	
	11	2004/0106141	06/03/04	Mischel et al.	
	12	2004/0132825	07/08/04	Bacopoulos et al.	
	13	2004/0132097	07/08/04	Bacus et al.	
	14	2004/0248151	12/09/04	Bacus et al.	
	15	2005/0043233	02/24/05	Stefanic et al.	
	16	2006/0211060	09/21/06	Haley et al.	
	17	2006/0234237	10/19/06	Amler et al.	
	18	2007/0020261	01/25/07	Slivkowski et al.	
	19	2007/0032513	02/08/07	Hennequin et al.	
	20	2007/0043009	02/22/07	Hennequin et al.	
	21	2007/0117815	05/24/07	Pluda et al.	
	22	2007/0197473	08/23/07	Frankel et al.	
	23	2007/0197568	08/23/07	Bunn et al.	
	24	2007/0281934	12/06/07	Buggy et al.	
	25	2008/0015190	01/17/08	Chakravarty et al.	
	26	2008/0015216	01/17/08	Belvedere et al.	
	27	2008/0033015	02/07/08	Belvedere et al.	
	28	2008/0085874	04/10/08	Kushner et al.	
	29	2008/0090233	04/17/08	Garcia et al.	
	30	2008/0096920	04/24/08	Belvedere et al.	
	31	2008/0182865	07/31/08	Witta et al.	
	32	2008/0234265	09/25/08	Witta et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	2	of	14	<b>Complete if Known</b>
				Application Number
				10/587,052
				Filing Date
				April 9, 2007
				First Named Inventor
				Paul A. Bunn Jr.
				Art Unit
				1642
				Examiner Name
				Sean E. Aeder
				Attorney Docket Number
				5941-65-PUS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	33	EP 659439	06/28/95	MERCK PATENT GMBH		
	34	WO 06/005955	01/19/06	LETTI SPA ISTITUTO DI RICERCHE		
	35	WO 06/061638	06/15/06	ANGELETTI P IST RICERCHE BIO		
	36	WO 06/115833	11/02/06	MERCK & CO INC		
	37	WO 06/115835	11/02/06	MERCK & CO INC		
	38	WO 06/115845	11/02/06	MERCK & CO INC		
	39	WO 07/002248	01/04/07	MERCK & CO INC		
	40	WO 07/029035	03/15/07	ANGELETTI P IST RICERCHE BIO		
	41	WO 07/029036	03/15/07	ANGELETTI P IST RICERCHE BIO		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 14 Attorney Docket Number 5941-65-PUS

<i>Complete if Known</i>			
Application Number			10/587,052
Filing Date			April 9, 2007
First Named Inventor			Paul A. Bunn Jr.
Art Unit			1642
Examiner Name			Sean E. Aeder
42	WO 07/052073	05/10/07	ANGELETTI P IST RICHERCHE BIO
43	WO 07/055941	05/18/07	MERCK & CO INC
44	WO 07/055942	05/18/07	MERCK & CO INC
45	WO 07/072080	06/28/07	ANGELETTI P IST RICHERCHE BIO
46	WO 07/087129	08/02/07	MERCK & CO INC
47	WO 07/087130	08/02/07	MERCK & CO INC
48	WO 07/093827	08/23/07	ANGELETTI P IST RICHERCHE BIO
49	WO 07/100657	09/07/07	MERCK & CO INC
50	WO 07/107594	09/27/07	ANGELETTI P IST RICHERCHE BIO
51	WO 07/127137	11/08/07	MERCK & CO INC
52	WO 07/136605	11/29/07	MERCK & CO INC
53	WO 08/010985	01/24/08	MERCK & CO INC
54	WO 08/033745	03/20/08	CURIS INC
55	WO 08/033749	03/20/08	CURIS INC
56	WO 2005/027972	03/31/05	NOVARTIS AG

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 4 of 14 Attorney Docket Number 5941-65-PUS

## *Complete if Known*

Application Number	10/587,052
Filing Date	April 9, 2007
First Named Inventor	Paul A. Bunn Jr.
Art Unit	1642
Examiner Name	Sean E. Aeder

57	WO 2005/070020	08/04/05	UNIV COLORADO		
58	WO 2005/117553	12/15/05	UNIV COLORADO		
59	WO 2006/005941 (WO 2005GB2729)	01/19/06	ANGELETTI P ISTITUTO DI RICERCHE BIO		
60	WO 2006/017214 (WO 2005US24512)	02/16/06	MERCK & CO INC		
61	WO 2006/017215 (WO 2005US24513)	02/16/06	MERCK & CO INC		
62	WO 2006/082428	08/10/06	TOPOTARGET UK LTD		
63	WO 2006/099396	09/21/06	UNIV COLORADO		
64	WO 2006/110478	10/19/06	NOVARTIS AG		
65	WO 2007/025044	03/01/07	SQUIBB BRISTOL MYERS CO		
66	WO 92/10588	06/25/92	AFFYMAX TECH NV		
67	WO 95/35505	12/28/95	UNIV LELAND STANFORD JUNIOR		
68	WO 97/10365	03/20/97	AFFYMAX TECH NV		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

5

of

14

***Complete if Known***

Application Number	10/587,052
Filing Date	April 9, 2007
First Named Inventor	Paul A. Bunn Jr.
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	5941-65-PUS

**OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)**

Examiner Initials*	Cite No. <sup>1</sup>	
	69	Al Moustafa et al., Lung Cancer. 37:49-56,2002.
	70	ALLAN, Nimotuzumab: Evidence of Clinical Benefit without Rash, The Oncologist, May 2005, Vol 10, No 9, pp 760-761
	71	Andrecheck et al. Proc Natl Acad Sc USA 2000; 97:3444-49.
	72	Arteaga, Sem Oncol 2002;29:3-9.
	73	Arteaga., Exp Cell Res 284:122-130,2003.
	74	Bailey et al., Lung Cancer 2003;41 :s71 (abstr).
	75	Barringer, et al., Gene, 89: 117-22 (1990)
	76	Barsky et al., Cancer 73: 1163-1170, 1994
	77	Bartlett et al., J Pathol 2003; 199:411-7.
	78	Batsche et al., Mol Cell Biol. 18(7):3647-58,1998.
	79	Beste G, Schmidt FS, Stibora T, Skerra A., Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1898-903.
	80	Bianco et al., Oncogene 2003;22:2812-22
	81	Bolos et al., J. Cell Sci. 116:499-511,2003.
	82	Breathnach et al., Cancer 86: 1165-1173, 1999

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

				<i>Complete if Known</i>	
Sheet	6	of	14	Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
				Attorney Docket Number	5941-65-PUS

83	Bremnes et al., J Clin Oncol. 20:2417-2428,2002.
84	Cano et al., Nat. Cell Biol. 2:76-83, 2000
85	Cappuzzo et al., J Clin Oncol. 21(14):2658-63,2003.
86	Cappuzzo et al., J. Natl Cancer Inst 2004;96: 1133-41.
87	Cappuzzo et al., Proc Am Soc Clin Oncol, 2004; 22 :3004
88	Cappuzzo et al. "Epidermal Growth Factor Receptor Gene and Protein and Gdinib Sensitivity in Non-Small-Cell Lung Cancer", Journal of the National Cancer Institute, Vol. 97, No. 9, May 4, 2005, pages 1-13
89	Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
90	Chinnadurai, Mol. Cell 9, 213-224, 2002.
91	Ciardiello and Tortora, Clin Cancer Res 2001;7:2958-70.
92	Ciardiello et al., Clin Cancer Res 2000;6:2053-63.
93	Comijn et al., Mol Cell ;7(6): 1267-78,2001.
94	Conacci-Sorrell et al., J Cell Biol. 163(4):847-57,2003.
95	Cowley et al., J Pathol. 179: 183-7, 1996
96	Cox,J R Stat Soc B 1972;34:187-220.
97	Datta SR, Genes and Development 1999; 13:2905-27.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				<i>Complete if Known</i>
Sheet	7	of	14	Application Number 10/587,052
				Filing Date April 9, 2007
				First Named Inventor Paul A. Bunn Jr.
				Art Unit 1642
				Examiner Name Sean E. Aeder
				Attorney Docket Number 5941-65-PUS

98	de Ruijter et al., Biochem J.370:737-749, 2003
99	Demetri et al., N Engl J Med 2002; 347:472-80.
100	DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM, Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 1996 Dec;14(4):457-60. (Abstract Only)
101	DiGiuseppe et al., Leukemia 13:1243-1253, 1999.
102	Druker et al., N Engl J Med 2001; 344: 1031-7.
103	DRUMMOND ET AL., "Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes", Clin Cancer Res, May 1 2005, 11(2), pages 3392-3401
104	Dumstrei et al., Development; 129(17):3983-94, 2002.
105	EGER et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 31 March 2005, Vol 24, No 14, pp 2375-85.
106	Frederick et al., Cancer Res 2000; 60, 1383-87.
107	Fricke et al., Oncology 66(2):150-9,2004.
108	FUINO ET AL., "Histon Deacetylase Inhibitor LAQ824 Down-Regulates Her-2 and Sensitizes Human Breast Cancer Cells to Transtuzumab, Taxotere, Gemcitabine, and Epothilone B." Molecular Cancer Therapeutics, 2003, Vol. 2, pages 971-984
109	Fukuoka et al., J Clin Oncol. 21:2237-2246,2003.
110	Furak et al., European J Cardio-Thoracic Surgery 23:818-823,2003.
111	Gandara et al., Clin Cancer Res, 2004 Jun 15;10(12 Pt 2):4205s-4209s
112	Giaccone et al., J Clin Oncol 2004;22:777-84

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	8	of	14	Attorney Docket Number	5941-65-PUS

113	Gore et al., 2004 ASCO Annual Meeting Proceedings Vol 22, No 14S (July 15 Supplement): 3026, 2004.
114	Guatelli, et al, Proc. Nat. Acad. Sci. USA, 87: 1874 (1990)
115	Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS, Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet. 1996 Dec;14(4):441-7. (Abstract Only)
116	Hajra et al., Cancer Res. 62:1613-1618,2002.
117	HAN et al., J Clin Oncol. 2005 Apr 10;23(11):2493-501. Epub 2005 Feb 14.
118	Herbst et al., J Clin Oncol. 2002;20:3815-25.
119	Hidalgo et al., J Clin Oncol. 2001;19:3267-79.
120	Hirsch et al., "Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas" Br J Cancer 86: 1449-1456,2002
121	Hirsch et al., J Clin Oncol, 2003;21:3798-807.
122	Hirsch et al., Lung Cancer 41 Suppl 1:S29-42, 2003.
123	Huelsken et al., Current Opin. Genet. Dev. 11,547-553,2001.
124	Janmaat et al., Clin Cancer Res 2003;9:2316-26.
125	Jemal et al., CA Cancer J Clin. 54(1):8-29,2004.
126	Jiang, Br J Surg 83: 437-446, 1996
127	Jorissen et al., Exp Cell Res 284:31-53,2003.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Sheet	9	of	14	Attorney Docket Number	5941-65-PUS
-------	---	----	----	------------------------	-------------

128	Kaplan and Meier, J Am Stat Assoc 1985;53:457-81.
129	Kelly et al., J Clin Oncol. 2001; 19:3210-8.
130	Kim et al., Clinical Cancer Res, 11:2244, 2005
131	Kintner, Cell 69: 225-236, 1992.
132	Kohler and Milstein, Nature 256:495-497, 1975
133	KRAKER et al. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl)benzamide] in HCT-8 colon carcinoma. Mol. Cancer. Ther., April 2003, Vol 2, No 4, pp 401-8.
134	Kris et al., J. Am. Med. Assoc. 290,2149-2158,2003.
135	Kris et al., Lung Cancer 2000; Suppl 1;72:233 abstract.
136	Kwoh, et al., Proc. Natl. Acad. Sci. USA, 86: 1173 (1989)
137	Landegren, et al., Science, 241: 1077 (1988)
138	Levitt and Koty, Investig New Drugs 1999;7:213-26.
139	Levitzki and Gazit, Science 267: 1782-8, 1995.
140	Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol. 1996 Dec;14(13):1675-80. (Abstract Only)
141	Lu et al., Cancer Cell. 4(6):499-515, 2003.
142	Lynch et al., N Engl J Med 350:2129-39,2004.

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number	10/587,052				
Filing Date	April 9, 2007				
First Named Inventor	Paul A. Bunn Jr.				
Art Unit	1642				
Examiner Name	Sean E. Aeder				
Sheet	10	of	14	Attorney Docket Number	5941-65-PUS

143	Mantel N, Cancer Chemother Rep 50:163-170,1966.
144	Marks et al., J Natl Cancer Inst (Bethesda),92:1210-6, 2000
145	Matei et al., Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation, Clinical Cancer Research, 15 January 2004, Vol 10, No 2, pp 681-690
146	Meinkoth et al., 1984, Anal. Biochem. 138, 267-284
147	MENDELSONH et al. Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. Journal of Clinical Oncology, 15 July 2003, Vol 21, No 14, pp 2787-2799.
148	Miller et al., J Clin Oncol. 2004;22: 1103-9.
149	Miller et al., Proc Am Soc Clin Oncol 2003;22 (abstract 2491).
150	Mitsudomi et al. J Clin Oncol. 23:2513, 2005
151	MONNERT "Histone Deacetylase Inhibitors", European Journal of Medicinal Chemistry, 2005, Vol. 40, pages 1-13
152	NIMANNAPALLI et al. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells. Cancer Research, 15 Aug 2003, Vol 63, No 16, pp 5126-35.
153	Ohira et al., Proc Natl Acad Sci USA. 100:10429-10434,2003.
154	Oken et al., Am J Clin Oncol, 1982; 5:649-655.
155	Ono et al., Mol Cancer Ther 2004;3 :465-72
156	O'Shannessy DJ, Brigham-Burke M, Soneson KK, Hensley P, Brooks I., Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. Anal Biochem. 1993 Aug 1;212(2):457-68. (Abstract Only)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	11	of	14	Attorney Docket Number	5941-65-PUS

	157	Ozawa et al., EMBO J. 8: 1711-1717, 1989.
	158	Paez et al., "EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy." Science (Wash DC) 304:1497-500, 2004.
	159	Pao et al., Proc Natl Acad Sci USA 101(36):13306-11, 2004.
	160	Parkin, The Lancet Oncology 2:533-543,2001.
	161	Parra et al., Brit J Cancer, 91: 208-212, 2004.
	162	Patel et al., Lung Cancer 41 :S56, 2003 (suppl2).
	163	Pece and Gutkind, J Biol Chem. 275(52):41227-33,2000.
	164	Pece et al., J Biol Chem 274(27):19347-51, 1999
	165	Perez-Soler et al., J Clin Oncol 2004;22:3238-47.
	166	Perez-Soler et al., Proc. Am. Soc. Clin. Oncol., 20: 310a (1235) 2001.
	167	Polowy et al., Proc Am Soc Clin Oncol 22: 2003 (abstr 2845), pages 1-3
	168	Postigo and Dean, Proc. Natl. Acad. Sci. USA 96, pp. 6683-6688, 1999.
	169	Qian et al.,EMBO J. 23:1739-84,2004.
	170	Ranson et al., J Clin Oncol. 2002;20:2240-50.
	171	Reginato et al., Nat Cell Biol. 5(8):733-40, 2003
	172	Reissmann et al., J Cancer Res Clin Oncol, 1999;125:61-70.

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Scan E. Aeder
Sheet	12	of	14	Attorney Docket Number	5941-65-PUS

173	Rosell et al.; Clin Cancer Res 2004;10:1318-25
174	Rosivatz et al., Int J Cancer 111(5):711-9, 2004.
175	Salomon et al., Crit Rev Oncol Hematol, 1995;19:183-232.
176	Satoh et al., Biocell. 27(1):47-55,2003.
177	Schiller et al., N Engl J Med 2002;346:92-8.
178	Schuster SC, Swanson RV, Alex LA, Bourret RB, Simon MI., Assembly and function of a quaternary signal transduction complex monitored by surface plasmon resonance. Nature. 1993 Sep 23;365(6444):343-7.
179	Sekido et al., Mol Cell Biol. 14:5692-700, 1994
180	Shepherd et al., Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7022.
181	Sirotnak et al., Clin Cancer Res 2000;6:4885-92
182	Slamon et al., N Engl J Med 2001; 344:783-92
183	Slamon et al., Science 235:177-182,1987.
184	Sordella et al., Science 2004;305:1163-7
185	Stirling R, Brunette E, Liggitt D, Gaensler K, Debs R., Aerosol gene delivery in vivo. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11277-81.
186	Sulzer et al., Am J. Respir, 1998, Vol. 157, pages 1319-1323
187	Suzuki et al., Lung Cancer;42(1):35-41, 2003.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	13	of	14	Attorney Docket Number	5941-65-PUS

188	Therasse et al, J Natl. Cancer Inst. 2000 Feb 2; 92(3):205-16; available at <a href="http://ctep.cancer.gov/forms/TherasseRECISTJNCI.pdf">http://ctep.cancer.gov/forms/TherasseRECISTJNCI.pdf</a>
189	Tracy et al., Cancer Res, 2004; 64:7241-44
190	van Grunsven et al., J Biol Chem. 278:26135-26145, 2003.
191	Verschueren et al., J Biol Chem. 274:20489-98, 1999
192	Vogel et al., J Clin Oncol, 2002;20:719-26.
193	West et al., Advanced bronchioalveolar carcinoma: a phase II trial of pac1/taxel by 96-h infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol. 2005 Jul;16(7):1076-80. Epub 2005 Apr 28.
194	WITTA ET AL, "Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors", Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, 7083
195	WITTA ET AL., "Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines", Cancer Res., January 15, 2006; 66(2), pages 944-50
196	Wu and Wallace, Genomics, 4: 560 (1989)
197	Yarden and Sliwkowski, Nat Rev Mol Cell Biol. 2:127-137,2001.
198	Zelent et al., Clin Cancer Res 10: 4622-4629,2004.
199	International Search Report for International (PCT) Patent Application No. PCT/US08/70930, mailed February 6, 2009 (Attorney's Ref. No. 5941-65-PUS-CIP-PCT)
200	Written Opinion for International (PCT) Patent Application No. PCT/US08/70930, mailed February 6, 2009 (Attorney's Ref. No. 5941-65-PUS-CIP-PCT)
201	International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2006/009078, issued September 12, 2007 (Attorney's Ref. No. 2848-79-PCT)
202	International Search Report for International (PCT) Patent Application No. PCT/US08/70924, mailed October 7, 2008 (Attorney's Ref. No. 5941-79-1-PCT)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

***Complete if Known***

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	14	of	14	Attorney Docket Number	5941-65-PUS

203	Written Opinion for International (PCT) Patent Application No. PCT/US08/70924, mailed October 7, 2008 (Attorney's Ref. No. 5941-79-1-PCT)
204	International Search Report for International (PCT) Patent Application No. PCT/US2006/009078, mailed February 22, 2007 (Attorney's Ref. No. 2848-79-PCT)
205	Written Opinion for International (PCT) Patent Application No. PCT/US2006/009078, mailed February 22, 2007 (Attorney's Ref. No. 2848-79-PCT)
206	International Search Report for International (PCT) Patent Application No. PCT/US05/18879, mailed May 2, 2008 (Attorney's Ref. No. 2848-70-PCT)
207	Written Opinion for International (PCT) Patent Application No. PCT/US05/18879, mailed May 2, 2008 (Attorney's Ref. No. 2848-70-PCT)
208	Written Opinion for International Patent Application No. SG 2007/06399-3, mailed October 8, 2008 (Attorney's Reference No. 5941-79-PSG)
209	Official Action for U.S. Patent Application No. 11/781,946, mailed November 19, 2008 (Attorney's Ref. No. 5941-65-PUS)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.